Michael D. Dale - 26 Feb 2026 Form 4 Insider Report for Axogen, Inc. (AXGN)

Reporting relationship: Chief Executive Officer
Issuer ticker: AXGN
Reported as of: 26 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Feb 2026, 16:20:02 UTC
Prior SEC filing: 12 Dec 2025
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Began, as attorney-in-fact for Michael Dale

Key filing fact

Michael D. Dale filed Form 4 for Axogen, Inc. (AXGN) on 27 Feb 2026.

Key facts

This page summarizes Michael D. Dale's Form 4 filing for Axogen, Inc. (AXGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Feb 2026, 16:20.

Change

Previous filing in this sequence was filed on 12 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001172346 Primary reporting owner

DALE MICHAEL D

Relationship: Chief Executive Officer
Address: 13631 PROGRESS BLVD.,, SUITE 400, ALACHUA
Signature: /s/ Mark Began, as attorney-in-fact for Michael Dale
Signature date: 27 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXGN transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +98,000
Change %
Price: $0.000000
Shares after: 98,000
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 98,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Footnote F2

All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.